Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 2
1986 8
1987 3
1988 5
1990 4
1991 1
1992 6
1993 3
1994 4
1995 3
1996 5
1997 2
1998 5
1999 8
2000 6
2001 7
2002 1
2003 4
2004 1
2007 2
2008 3
2009 2
2010 1
2011 3
2012 4
2013 5
2014 2
2015 1
2016 1
2017 4
2018 5
2019 2
2020 5
2021 1
2022 1
2023 4
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
NCCN: Multiple myeloma.
Traynor AE, Noga SJ; NCCN Multiple Myeloma Practice Guidelines Panel. Traynor AE, et al. Among authors: noga sj. Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):78-87. Cancer Control. 2001. PMID: 11760563 Review.
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Kumar S, et al. Among authors: noga sj. Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15. Blood. 2012. PMID: 22422823 Free article. Clinical Trial.
Treating Multiple Myeloma Patients With Oral Therapies.
Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. Kumar SK, et al. Among authors: noga sj. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):243-251. doi: 10.1016/j.clml.2017.02.024. Epub 2017 Mar 7. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28347676 Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
120 results